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Background: The proliferative index (PI) is a powerful prognostic factor in mantle cell lymphoma (MCL); however, its
utility is hampered by interobserver variability. The mantle cell international prognostic index (MIPI) has been reported
to have prognostic importance. In this study, we determined the prognostic value of the PI as determined by
quantitative image analysis in MCL.
Patients and methods: Eighty-eight patients with adequate tissue were included in this analysis. Patients were
treated with one of two treatment programs: sequential therapy with high-dose therapy consolidation or
radioimmunotherapy followed by combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and
prednisone. Patients were divided into four groups based on PI (<10%, 10%–29.9%, 30%–49.9%, and >50%), and
outcomes were analyzed.
Results: Thirty percent was identiﬁed as the optimal cut-off for PI. By univariate analysis, intensive treatment and
a low PI were associated with a superior progression-free survival (PFS); only PI was associated with overall survival.
By multivariate analysis, both intensive treatment and PI correlated with PFS. The MIPI had no prognostic impact.
Conclusions: PI is the most important prognostic factor in MCL. The cut-off of 30% is clinically meaningful and can
be used to tailor the intensity of therapy in future clinical trials.
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introduction
The management of patients with mantle cell lymphoma
(MCL) lacks an accepted standard of care. CHOP (combination
chemotherapy with cyclophosphamide, adriamycin, vincristine,
and prednisone) or CHOP-like chemotherapy regimens are
associated with a median overall survival (OS) between 3 and 5
years [1–3]. Adding rituximab to CHOP (R-CHOP) or
ﬂudarabine-based chemotherapy has improved the overall
response, but progression-free survival (PFS) and OS are not
improved [4, 5]. Intensive regimens have been evaluated
including fractionated cyclophosphamide, doxorubicin,
vincristine, dexamethasone alternating with high-dose
methotrexate—cytarabine (R-HyperCVAD/R-MA) and
sequential chemotherapy followed by consolidation with high-
dose therapy and autologous stem-cell rescue (HDT/ASCR) [6,
7]. For those patients who could tolerate more intensiﬁed
treatment regimens, event-free survival and OS at 5–6 years
improves to 48%–56% and 65%–70%, respectively [7, 8]. In
contrast, some advocate a less intensive ‘watch and wait’
approach to MCL, with treatment when clinically indicated [9].
A better understanding of MCL prognostic factors would
identify patients for whom intensiﬁed treatment is most
appropriate. Currently, the best deﬁned prognostic factors are
the proliferative index (PI) and the mantle cell international
prognostic index (MIPI).
Several studies have demonstrated that PI estimated by
immunohistochemistry (IHC) for Ki-67 predicts clinical
outcome. The PI inversely correlates with OS irrespective of
treatment type [7, 10–18]. However, the method of
determining PI by IHC has varied from a semiquantitative
estimation to direct counting of 1000 cells per case. Different
groups have reported variable cut-offs between 10% and 60%
[7, 10–12, 14, 16–18]. This variability likely arises at least in
part from interobserver variation in the interpretation of IHC
for Ki-67.
MIPI is a better predictor of OS than the International
Prognostic Index in a population treated with a variety of
approaches including anthracycline-based chemotherapy with
or without rituximab, as well as some patients undergoing
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predict outcome for patients treated with R-HyperCVAD/R-
MA [20].
Thus, both PI estimated by Ki-67 IHC and the MIPI have
limitations in the prognostication of MCL. In this study,
a highly reproducible computer-based quantitative image
analysis (QIA) was employed to overcome the interobserver
variability in determining PI. We sought to determine a cut
point for PI that could distinguish outcome in patients with
MCL. Furthermore, we sought to determine the prognostic
value of the MIPI, sMIPI, and Ki-67-MIPI.
patients and methods
One hundred and eleven patients with a new diagnosis of MCL between
1998 and 2008 participated in a treatment plan of sequential therapy with
four cycles of CHOP-14 6 rituximab induction followed by two or three
cycles of ICE (ifosfamide, carboplatin, and etoposide) 6 rituximab
chemotherapy [(R)ICE]. The number of cycles of (R)ICE chemotherapy
was determined by functional imaging after induction. Patients underwent
consolidation with HDT with combination of carmustine, etoposide,
cytarabine and melphalan followed by ASCR. Between April 2001 to
December 2004, 24 patients were included in a prospective study of
sequential
131I-tositumomab followed by six cycles of CHOP-21
[radioimmunotherapy (RIT-CHOP)] [21]. The diagnosis of MCL was
conﬁrmed by review of diagnostic biopsies. A total of 88 patients with
adequate tissue were included in the analysis (69 from the HDT/ASCR
group and 19 from the RIT-CHOP group). This study was approved by the
Memorial Sloan-Kettering Cancer Center Institutional Review Board under
a waiver of authorization.
MIPI
The MIPI, MIPI combined with Ki-67, and the sMIPI were determined as
originally described [19].
immunohistochemistry
Eighty-eight patients had formalin-ﬁxed parafﬁn-embedded (FFPE) tumor
tissue available for IHC for Ki-67 staining using the MIB1 mouse mAb
(Immunotech, Westbrook, ME) at a 1:500 dilution. Standard avidin–
biotin–peroxidase complex techniques were used for IHC carried out on 5-lm
sections of FFPE tissue. Antigen retrieval in heated citrate buffer at pH 6.0
was applied for all antibodies. Positive control tissues were stained in
parallel with the study cases. Slides were counterstained with hematoxylin.












<60 49 (71) 7 (37)
‡60 20 (29) 12 (63)
LDH 0.40
Normal 43 (66) 15 (79)
High 22 (34) 4 (21)
NA 04 0
Performance status (ECOG) 0.68
0–1 60 (88) 18 (95)
2 8 (12) 1 (5)
NA 1 0
Ann Arbor stage 0.99
I or II 3 (4) 0
III or IV 66 (96) 19 (100)
Bone marrow involvement 0.09
No 17 (25) 9 (47)
Yes 52 (75) 10 (53)
MIPI 0.98
Low 34 (55) 10 (53)
Intermediate 18 (29) 6 (32)
High 10 (16) 3 (16)
NA 7
sMIPI 0.28
Low 33 (52) 9 (47)
Intermediate 20 (31) 9 (47)
High 11 (17) 1 (6)
NA 5
MIPI-Ki-67 0.30
Low 11 (19) 3 (16)
Intermediate 29 (49) 13 (68)
High 19 (32) 3 (16)
NA 10 –
Ki-67, % 0.06
<10 15 (22) 7 (37)
10–29.9 23 (33) 10 (53)
30–49.9 17 (25) 1 (5)
‡50 14 (20) 1 (5)
aR-CHOP-14 + (R)ICE + autologous stem-cell transplant.
bTositumomab followed by CHOP.
cChi-square test.
RIT-CHOP, radioimmunotherapy + CHOP; CHOP, cyclophosphamide,
adriamycin, vincristine, prednisone; LDH, lactose dehydrogenase; NA, not
available; ECOG, Eastern Cooperative Oncology Group; MIPI, mantle cell
international prognostic index; sMIPI, simpliﬁed MIPI; R-CHOP,
rituximab to CHOP; (R)ICE, ifosfamide, carboplatin, and etoposide) 6
rituximab chemotherapy.










Intensive (n = 69) 65 84
Conventional (n = 19) 26 84
MIPI 0.83 0.13
Low (n = 44) 62 83
Intermediate (n = 24) 51 94
High (n = 13) 48 69
sMIPI 0.86 0.92
Low (n = 42) 63 82
Intermediate (n = 28) 54 92
High (n = 11) 43 75
MIPI-Ki-67 0.87 0.13
Low (n = 14) 58 100
Intermediate (n = 42) 60 89
High (n = 22) 46 80
aLog-rank test.
PFS, progression-free survival; OS, overall survival; MIPI, mantle cell
international prognostic index; sMIPI, simpliﬁed MIPI.
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Ki-67-stained slides were scanned with the Aperio ScanScope XT (Aperio,
Vista, CA) using a (20 objective. Whole slide images were analyzed with the
Aperio nuclear IHC algorithm. Brieﬂy, brown (3,3-diaminiobenzidine) and
blue (hematoxylin) colors were separated spectrally. Blue cells that were
also brown were scored as positive, and cells that were blue only were
scored as negative. The percentage of positive cells was calculated as brown
divided by the sum of brown and blue cells. The QIA algorithm counted
a median of 571 358 cells per slide (1504–5 476 582).
cut-off determination
The sample size was not large enough to independently determine
a clinically relevant cut point for the PI. We chose to validate the PI cut-offs
of 10% and 30% as proposed by Determan et al. [10] and used in Geisler
et al. [7]. Moreover, we tested a 50% cut-off to explore the impact of
a higher PI on survival.
statistical analysis
Patient outcomes were evaluated by intention to treat. Patients who
received any of the planned treatment (CHOP-14 for the HDT/ASCR group
or radioimmunotherapy for the RIT-CHOP group) were included
regardless of completing treatment. OS was calculated from diagnosis until
death from any cause or the last follow-up visit. PFS was determined from
the beginning of the treatment until progression, relapse, death from any
cause, or last follow-up visit. Categorical data were analyzed by the chi-
square test and continuous data by the Mann–Whitney test. Survival curves
are per the method of Kaplan–Meier; comparative analyses were carried
OUT by log-rank test. The Cox proportional hazards model was used for
the multivariate analysis. Statistical analyses were conducted using SPSS
version 17.0 (SPSS, Chicago, IL).
results
Patient characteristics (N = 88) are shown in Table 1, with
a comparison of the HDT/ASCR and RIT-CHOP treatment
groups. There was an expected male predominance (76%). The
median age was 57 years (range 34–77 years); patients in the
RIT-CHOP group were signiﬁcantly older. Lactose
dehydrogenase was abnormal in 26 of 84 available patients
(31%). Bone marrow disease was present in 62 (71%) patients.
Figure 1. Progression-free survival (A) and overall survival (B) of patients with mantle cell lymphoma according to the proliferative index (Ki-67): <10%
(blue); 10%–29.9% (green); 30%–49.9% (yellow); ‡50% (pink).
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77%). The MIPI and its variants were balanced between
treatments. The PI was higher in patients receiving HDT/ASCR
(median 29% versus 17%, P = 0.002).
Sixty-nine patients were treated according to the intensive
protocol, and 64 were submitted to autogeneic stem-cell
transplantation (93%). The reasons for not proceeding to
HDT/ASCR were disease progression (one), allogeneic SCT
(one), heart disease (one), renal disease (one), and one death
from sepsis during ICE.
survival analysis
The median follow-up of surviving patients was 4.8 years (1.0–
11.5 years). Thirty-seven patients relapsed, and 20 died during
this period. The median PFS was 5 years; the median OS has
not been reached (5-year OS 76%). There was no difference in
PFS or OS with respect to rituximab use in the patients
undergoing HDT/ASCR (4-year PFS 58% versus 50%, P = 0.66,
and 4-year OS 87% versus 77%, P = 0.17). PFS was superior for
patients in the HDT/ASCR group compared with the RIT-
CHOP group (65% versus 26% at 4 years, P < 0.01); there was
no difference in the OS between treatment groups (84% at 4
years in both groups) (Table 2).
proliferative index
The distribution of patients according to PI subgroups is
summarized in Table 1; survival is depicted in Figure 1. The
patients were divided into four groups based on PI: 0–9.9,
10–29.9, 30–49.9, and >50%) (Figure 1A). However, as there
was no difference in PFS or OS in patients with PI <10% and
PI 10%–29.9%, the prognostic groups could be reduced to
two based on the cut-off of 30% for PFS and 50% for OS
( F i g u r e1 B ) .AP Ic u t - o f fo f50% performed no better than
a cut-off of 30% for PFS. Furthermore, the 30% cut-off
split the sample into two subgroups of a reasonable number
of patients (low PI, 53 patients; high PI, 33 patients)
with prognostic relevance to both PFS and OS and was
chosen as the cut-off for the multivariate analysis (Figure 2A
and C). More importantly, there is a plateau in the PFS for
patients with a PI <30% (Figure 2A). The results were
similar when only the HDT/ASCR patients were analyzed
(data not shown).
MIPI
The MIPI, sMIPI, and MIPI-Ki-67 failed to show prognostic
signiﬁcance for OS or PFS (Table 2, Figure 3).
Figure 2. Progression-free survival (A, B) and overall survival (C, D) according to the proliferative index (PI) higher or lower than 30% (A, C) or 50%
(B, D) in 88 patients with mantle cell lymphoma.
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In the Cox regression analysis, the PI [hazard ratio (HR) 2.75,
95% conﬁdence interval (CI) 1.43–5.30)] and the treatment
group (HR 4.52, 95% CI 2.32–8.80) retained their prognostic
signiﬁcance for PFS. We did not carry out multivariate analysis
for OS because only PI showed prognostic importance in the
univariate analysis.
impact of treatment type according to PI
Among the low-PI patients, treatment type had a profound
impact on PFS (P < 0.001) but not OS (P = 0.10) (Figure 4). At
5 years, 82% of patients who underwent HDT/ASCR remained
free of progression as compared with 24% after RIT-CHOP.
Furthermore, there were no relapses after 5 years among the
patients who underwent HDT/ASCR (N = 15). There were not
enough patients with high PI treated with RIT-CHOP to
analyze the impact of treatment.
discussion
Gene expression proﬁling has identiﬁed proliferation signature
as a powerful predictor of outcome in MCL [22]. Several
studies have shown that the PI estimated by percent of Ki-67-
positive cells can be used to predict outcome [7, 10–18].
However, determination of PI by Ki-67 IHC is subject to
interobserver variation limiting study-to-study comparison
(R. Schaffel et al., unpublished data) [23]. Approaches have
included manual counting and QIA. We applied QIA to Ki-67
determination in MCL and found it to be robust and
reproducible (Schaffel et al., unpublished data) [10, 12, 15, 18].
In the current study, only PI determined by QIA was
a prognostic factor for OS. Patients could be divided into two
groups based on PI with the best cut-off value for PFS (30%)
and for OS (50%). However, for practical purposes, a single
cut-off was chosen for both PFS and OS using the 30% value.
This generated two groups that retained prognostic signiﬁcance
Figure 3. Progression-free survival (A) and overall survival (B) of patients with mantle cell lymphoma according to mantle cell international prognostic
index score.
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in two other large studies [7, 10]. In multivariate analysis, the
PI was strongly associated with PFS and was the only factor that
predicted OS.
The possibility that a subgroup of patients with MCL could
haveaprolongeddisease-freesurvival(DFS)wasﬁrstdescribedby
Geisleretal.andhasrecentlybeenconﬁrmed[7,24].Inourstudy,
we corroborated this ﬁnding and showed that all patients who
achieved long-term DFS (>5 years) had a PI of <30%. Moreover,
thissubsetofpatientscouldbefoundinbothtreatmentprograms,
although the proportion was greater in the group consolidated
with HDT/ASCR. The hypothesis that those patients may be
cured is intriguing and requires longer follow-up.
Our study had some limitations. The relatively small number
of patients precluded an independent determination of the PI
cut-off. Rather, we sought to conﬁrm cut-off values that had
been previously reported. Furthermore, the sample size may
have been too small to detect differences in outcome for PI cut-
offs of <10% and 10%–29.9%. The subgroup of patients treated
with RIT-CHOP included an insufﬁcient number of patients
with high-risk MIPI or high PI.
We also sought to determine whether the MIPI, sMIPI, or
Ki-67-MIPI applied to our patient population. The MIPI and
its variants were based on a population of 455 patients treated
predominantly with CHOP 6 R (87%), with only 80 patients
(18%) treated with HDT/ASCR consolidation [19]. In that
Figure 4. Progression-free survival (A) and overall survival (B) of patients with mantle cell lymphoma and a proliferative index <30% according to the
planned therapy [high-dose chemotherapy with autologous stem-cell rescue (HDT/ASCR) or radioimmunotherapy followed by combination chemotherapy
with cyclophosphamide, doxorubicin, vincristine and prednisone (RIT-CHOP)].
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undergoing HDT/ASCR consolidation was not shown.
Application of the sMIPI to 97 patients receiving intensive
treatment with R-HyperCVAD/R-MA failed to demonstrate the
ability of this model to predict outcome [20].
In the current study, we also could not conﬁrm that MIPI and
its variants predicted outcome. There are several possible
explanations. First,the medianfollow-upis longer inthecurrent
study; the early separation in the curves disappears beyond 4.5
years (Figure 3B). Second, in the current study, median OS was
longer than in the original dataset for the intermediate (not
reached versus 51 months) and high-risk groups (not reached
versus 29 months) [19]. This may be the consequence of more
effective therapy available after ﬁrst line than was available for
patientsintheoriginalmodel.Thus,withthetreatmentregimens
used in this study, we are unable to conﬁrm the utility of the
MIPI and its variants to predict outcome.
In conclusion, PI is the most important prognostic factor in
MCL, and the 30% cut-off was conﬁrmed in our study. In
future clinical trials, 30% PI may be a useful parameter. QIA
may help overcome the center-to-center variability in the
determination of PI and increase general applicability.
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